NRx Pharmaceuticals (NRXPW) Stock Price, News & Analysis

Company Overview

NRx Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company developing novel therapies for neurodegenerative, neuropsychiatric and infectious diseases. The company's core technology platforms include nanocatalytic gold particles and proprietary small‐molecule compounds designed to modulate cellular energy metabolism, reduce oxidative stress and restore immune balance. NRx is advancing multiple candidates through preclinical and clinical development with the goal of addressing unmet medical needs in conditions ranging from amyotrophic lateral sclerosis (ALS) and Parkinson’s disease to bipolar depression and post‐traumatic stress disorder (PTSD).

The company’s lead program, CNM‐Au8, is a stable nanocrystal formulation of gold designed to catalyze neuronal bioenergetics and provide antioxidant activity. CNM‐Au8 is being evaluated in Phase II trials for ALS (REVITALISE) and Parkinson’s disease (RESCUE‐PD). In parallel, NRx is developing NRX‐101, an oral fixed‐dose combination intended to treat acute suicidal ideation and behavior in bipolar depression, and NRX‐102 for PTSD. The pipeline also includes TheraKine, an immunomodulatory cytokine formulation being explored for hospitalized COVID-19 patients, and additional anti‐inflammatory assets in earlier stages of research.

Founded to commercialize assets licensed from third‐party research organizations, NRx Pharmaceuticals is headquartered in the United States and serves patients and healthcare markets in North America, Europe and beyond. The company’s strategy centers on advancing its lead candidates through pivotal trials, securing regulatory designations where possible, and forming partnerships to support late‐stage development and eventual commercialization. NRx is led by a management team with experience in drug development, regulatory affairs and commercial strategy, and is publicly traded on the Nasdaq Capital Market under the symbol NRXPW.

Key Stats

• Today's Range: $0.07 to $0.09
• 50-Day Range: $0.06 to $0.10
• 52-Week Range: $0.04 to $0.50
• Volume: 973 shs
• Average Volume: 17,928 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NRXPW Stock Analysis - Frequently Asked Questions

How have NRXPW shares performed this year?

NRx Pharmaceuticals' stock was trading at $0.1280 at the beginning of 2025. Since then, NRXPW stock has decreased by 39.1% and is now trading at $0.0780.

How do I buy shares of NRx Pharmaceuticals?

Shares of NRXPW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NRXPW
• CIK: 1719406
• Web: www.nrxpharma.com
• Phone: 484 254 6134
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A